Chronic Lymphocytic Leukemia, An Issue of Hematology/Oncology Clinics of North America

1st Edition, Volume 35-4 - July 1, 2021
Editor: Jennifer R. Brown︎
Language: English
Hardback ISBN:
9 7 8 - 0 - 3 2 3 - 8 9 6 9 2 - 4
eBook ISBN:
9 7 8 - 0 - 3 2 3 - 8 9 6 9 3 - 1

This issue of Hematology/Oncology Clinics, guest edited by Dr. Jennifer R. Brown︎, will focus on Chronic Lymphocytic Leukemia. This issue is one of six selected each year by our se… Read more

Chronic Lymphocytic Leukemia, An Issue of Hematology/Oncology Clinics of North America

Purchase options

Info / Buy

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote

This issue of Hematology/Oncology Clinics, guest edited by Dr. Jennifer R. Brown︎, will focus on Chronic Lymphocytic Leukemia. This issue is one of six selected each year by our series consulting editors, Dr. George P. Canellos and Dr. Edward J. Benz. Topics discussed in this issue will include: Chronic Lymphocytic Leukemia: Do We Know the Cell of Origin Yet?; Significance of BCR Stereotypy; Prognostic and Predictive Implications of Cytogenetics and Genomics; Role of Epigenetics in Chronic Lymphocytic Leukemia; Genomics of Resistance to Targeted Therapies; First Line Therapy for Chronic Lymphocytic Leukemia; The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia Therapy; BTK Inhibitors; Minimal Residual Disease; Should Undetectable MRD Be the Goal of Chronic Lymphocytic Leukemia Therapy?; Management of Chronic Lymphocytic Leukemia after Progression on BTK Inhibitors; Role of PI3K Inhibitors in Chronic Lymphocytic Leukemia; Can We Restore the Immunodeficiency of Chronic Lymphocytic Leukemia?; and Immune Therapy for Chronic Lymphocytic Leukemia

Cover image
Title page
Table of Contents
Copyright
Contributors
Forthcoming Issues
Preface
Potential Relevance of B-cell Maturation Pathways in Defining the Cell(s) of Origin for Chronic Lymphocytic Leukemia
Key points
Introduction
Normal B-lymphocyte development and maturation
Features of chronic lymphocytic leukemia cells to consider when assigning cell of origin
Scenarios addressing the potential relevance of B-cell maturation pathways in defining the cells of origin in chronic lymphocytic leukemia
Clinics care points
The Significance of B-cell Receptor Stereotypy in Chronic Lymphocytic Leukemia: Biological and Clinical Implications
Key points
Introduction
Assessing B-cell receptor immunoglobulin stereotypy in large chronic lymphocytic leukemia cohorts: the 7000-patient series
Assessing B-cell receptor immunoglobulin stereotypy in large chronic lymphocytic leukemia cohorts: the 30,000 series
Higher-order connections between stereotyped subsets: the case of subset #2
Ontogenetic considerations: subset-specific scenarios
Chronic lymphocytic leukemia stereotypes in the normal B-cell receptor immunoglobulin repertoire: on the road to chronic lymphocytic leukemia?
Beyond the primary sequence level: stereotyped B-cell receptor immunoglobulin structures
Biological properties of stereotyped subsets
Clinical considerations: B-cell receptor stereotypy as a prognostic marker
Summary
Prognostic and Predictive Implications of Cytogenetics and Genomics
Key points
Introduction
Genomic landscape of chronic lymphocytic leukemia
Future perspectives/Summary
Clinics care points
Genomics of Resistance to Targeted Therapies
Key points
Introduction
Genetic aberrations associated with poor prognosis in chronic lymphocytic leukemia
Genomic alterations leading to Bruton tyrosine kinase inhibitor resistance
Genomic alterations leading to PI3k inhibitor resistance
Genomic alterations leading to venetoclax resistance
Summary
Clinics care points
First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?
Key points
A revolution in the care of untreated chronic lymphocytic leukemia
Bruton tyrosine kinase inhibitors
Venetoclax
Comparing novel agents
Combination novel therapy
Discussion
Clinics care points
The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia: TP53 Disruption, Richter, and Beyond
Key points
TP53 disruption continues to present a clinical challenge
TP53 function and known gene structure
Common TP53 disruption in chronic lymphocytic leukemia
Trials of Bruton tyrosine kinase inhibitors in TP53-disrupted patients
Trials of BCL-2 inhibitor in TP53-disrupted patients
Trials of PI3K inhibitor in TP53-disrupted patients
TP53 disruption, a common aberration in double refractory chronic lymphocytic leukemia
Richter transformation: still an unmet need
Summary
Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Beyond Ibrutinib
Key points
Introduction
Discussion
Efficacy
Toxicity
Resistance
Summary
Clinics care points
Disclosures
Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?
Key points
Background
Methods of minimal residual disease measurments
Minimal residual disease outcomes with chemotherapy and chemoimmunotherapy
Minimal residual disease outcomes with targeted agents
Minimal residual disease outcomes after cellular therapy
Using minimal residual disease in the clinic: Open challenges
Outlook
Clinics care points
Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton’s Tyrosine Kinase Inhibitors
Key points
Introduction
Reasons for discontinuation and mechanisms of resistance
Treatment of chronic lymphocytic leukemia following Bruton’s tyrosine kinase inhibitor discontinuation
Summary
Clinics care points
Conflict of interest disclosure statement
The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia
Key points
Introduction
Molecular mechanisms of phosphatidylinositol 3-kinase signaling
Physiologic role of phosphatidylinositol 3-kinase signaling in B lymphocytes and rationale for targeting phosphatidylinositol 3-kinase enzymes in chronic lymphocytic leukemia
A new beginning: early success in relapsed disease
The midlife crisis: challenges with toxicities limit clinical use and development
Resurrection: recent approaches to retain efficacy while mitigating toxicity
Future directions
Summary
Clinics care points
Can Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?
Key points
Introduction
Disease-related immunodeficiency
Treatment-related immune changes
Strategies to boost immunity
Discussion
Clinics care points
Immune Therapy for Chronic Lymphocytic Leukemia: Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and Beyond
Key points
Introduction
Discussion
Future directions
Summary